Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Nutrients|September 23, 2022
Discovery of Pinostrobin as a Melanogenic Agent in cAMP/PKA and p38 MAPK Signaling PathwayJeong-Hyun Yoon, Kumju Youn, Mira Jun
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 7, 2021
Protective effect of sargahydroquinoic acid against Aβ25-35-evoked damage via PI3K/Akt mediated Nrf2 antioxidant defense systemJeong-Hyun Yoon, Kumju Youn, Mira Jun
Metabolic Syndrome and Related Disorders|September 3, 2020
Metabolic Syndrome and Parkinson's Disease Incidence: A Nationwide Study Using Propensity Score MatchingJi-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon
Scientific Reports|March 21, 2024
The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunctionSu-Bin Lee, Mi Hyeon Jin, Jeong-Hyun Yoon
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 22, 2022
Decursin prevents melanogenesis by suppressing MITF expression through the regulation of PKA/CREB, MAPKs, and PI3K/Akt/GSK-3β cascadesHyungyeong Choi, Jeong-Hyun Yoon, Kumju Youn, et al.
Medicine|July 25, 2026
Sex-divergent metabolic pathways in the association between vitamin D status and metabolic-associated fatty liver diseaseKwang Min Kim, Mi Hyeon Jin, Jeong-Hyun Yoon
Clinics and Research in Hepatology and Gastroenterology|December 4, 2020
Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control studyKwang Min Kim, Ji Hye Roh, Sangjin Lee, et al.
Scientific Reports|February 4, 2021
Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver diseaseKwang Min Kim, Ji-Hye Roh, Sangjin Lee, et al.
BMC Musculoskeletal Disorders|January 3, 2024
The impact of Renin-Angiotensin System Inhibitors on bone fracture risk: a nationwide nested case-control studyKwang Min Kim, Eun Jung Hwang, Sangjin Lee, et al.
Journal of Patient Safety|April 2, 2026
Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents (ESA): Disproportionality Analysis Using the FDA Adverse Event Reporting SystemMihyun Park, Haesuk Park, In-Hwan Baek, et al.
Pageof 8